-
Mashup Score: 3Intrathecal hydrocortisone for treatment of children and young adults with CAR T‐cell immune‐effector cell‐associated neurotoxicity syndrome - 6 month(s) ago
Immune-effector cell-associated neurotoxicity syndrome (ICANS) is a significant toxicity occurring with chimeric antigen receptor (CAR) T-cell therapy, with first-line treatment options including sup…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Use of Early Intrathecal Therapy to Manage High-Grade ICANS - 6 month(s) ago
This case series describes the use of early intrathecal steroid administration to manage high-grade and steroid-refractory immune effector cell-associated neurotoxicity syndrome among patients with B-cell non-Hodgkin lymphoma.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern? - 6 month(s) ago
Chimeric antigen receptor (CAR) T-cell systemic immunotherapy has revolutionized how clinicians treat several refractory and relapsed hematologic malignancies. Due to its peculiar mechanism of action, CAR T-cell-based therapy has enlarged the spectrum of neurological toxicities. CAR T-cell-associated neurotoxicity—initially defined as CAR T-cell-related encephalopathy syndrome (CRES) and currently coined within the acronym ICANS (immune effector cell-associated neurotoxicity syndrome)—is perhaps the most concerning toxicity of CAR T-cell therapy. Importantly, hematologic malignancies (especially lymphoid malignancies) may originate in or spread to the central nervous system (CNS) in the form of parenchymal and/or meningeal disease. Due to the emergence of deadly and neurological adverse events, such as fatal brain edema in some patients included in early CAR T-cell trials, safety concerns for those with CNS primary or secondary infiltration arose and contributed to the routine exclusio
Source: www.frontiersin.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Pretransplantation EASIX Score Predicts Nonrelapse and Overall Mortality of Adult Patients Undergoing Single-Unit Unrelated Cord Blood Transplantation - 8 month(s) ago
The Endothelial Activation and Stress Index (EASIX) is a laboratory-based score used to estimate endothelial damage occurring after hematopoietic cell…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 521FDA approves first cell therapy for type 1 diabetes - 10 month(s) ago
Discover the world’s best science and medicine | Nature.com
Source: www.nature.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 2Nueva terapia CAR-T 'made in Spain' contra el mieloma múltiple - 10 month(s) ago
La terapia CAR-T (de las siglas linfocitos T con un receptor quimérico frente a antígeno, en inglés) ARI0002h de desarrollo propio (académica, no industrial) del Hospital…
Source: ELMUNDOCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3How I treat unique and difficult-to-manage cases of CAR T-cell therapy–associated neurotoxicity - 12 month(s) ago
With 6 chimeric antigen receptor (CAR) T-cell products approved by the US Food and Drug Administration and many more showing promise in clinical trials, the nee
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Introduction to a How I Treat series on emergent CAR T-cell toxicities - 12 month(s) ago
When the Food and Drug Administration (FDA) approved the first 2 chimeric antigen receptor T-cell therapy (CAR-T) products in 2017, the agency deemed that both
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2How I treat refractory CRS and ICANS after CAR T-cell therapy - 12 month(s) ago
With 6 chimeric antigen receptor (CAR) T-cell products approved by the US Food and Drug Administration and many more showing promise in clinical trials, the nee
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 7Targeted Therapy in Acute Lymphoblastic Leukaemia - 12 month(s) ago
The last decade has seen a significant leap in our understanding of the wide range of genetic lesions underpinning acute lymphoblastic leukaemia (ALL). Next generation sequencing has led to the identification of driver mutations with significant implications on prognosis and has defined entities such as BCR-ABL-like ALL, where targeted therapies such as tyrosine kinase inhibitors (TKIs) and JAK…
Source: MDPICategories: Hematologists1, Latest HeadlinesTweet
#Intrathecal hydrocortisone for treatment of children and young adults with #CARTcell #ICANS immune‐effector cell‐associated neurotoxicity syndrome - Shalabi - Pediatric Blood & Cancer - Wiley Online Library https://t.co/tYAd61IND9